Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak

Fig. 3

Proportion of patients with abnormal lung examination parameters at enrollment. Proportion of patients with abnormal pulmonary function test parameters (A); DLCO < 80% of predicted (B); abnormal exhaled NO level (C); positive results for the bronchial provocation test (D). VC: vital capacity; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; MEF50: maximal expiratory flow after 50% of the FVC has been not exhaled; MEF25: maximal expiratory flow after 25% of the FVC has not been exhaled; MMEF: maximal mid-expiratory flow; MVV: maximal ventilatory volume; NO: nitric oxide; DLCO: diffusion capacity for carbon monoxide; FeNO50: exhaled NO at a flow rate of 50 mL/s; FeNO200: exhaled NO at a flow rate of 200 mL/s; CaNO: concentration of alveolar NO; BPT: bronchial provocation test; ICS: inhaled corticosteroid group; NICS: non-inhaled corticosteroid group

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us